Researchers led by Dr. Ming Li at Memorial Sloan Kettering Cancer Center investigate the molecular mechanisms of immune regulation and its role in cancer. They aim to uncover new biological insights to target the immune system for cancer therapy, building on recent advancements in immunotherapy.
Researchers discovered five types of macrophages in fat tissue, with one subtype promoting inflammation and another quelling it. The findings challenge the long-held assumption that pro-inflammatory macrophages are solely responsible for obesity-related inflammation.
Macrophages produce polyamines spermidine and spermine, which benefit epithelial cells, promoting their proliferation and defense mechanisms. This "commensal metabolism" supports the efficient self-renewal of the intestinal epithelium.
A new study reveals that changing nutrient use can reprogram immune cells, potentially treating cancer and infections. By blocking choline metabolism, researchers found a 'tremendous reprogramming of the immune profile' in mice, suggesting this knowledge could lead to novel therapies.
A team of researchers at Mays Cancer Center has identified protein markers that could signal the early development of metastatic lung cancer. These markers have led to a $1.6 million grant and will pave the way for a clinical trial in patients with advanced lung cancer.
Researchers have developed a novel zebrafish xenograft platform to screen for novel treatments for glioblastoma, an aggressive brain tumor. The platform uses zebrafish avatars to model glioblastoma cells from individual patients, allowing researchers to identify patient-specific targets and potential treatments.
A new study reveals that COVID-19 triggers a dangerous immune response in hardened fatty deposits lining the heart's largest blood vessels. This inflammation can lead to immediate and longer-lasting heart issues, including plaque rupture and blockage of blood flow.
A team of scientists has developed a method to detect active Cullin-RING ligases (CRLs), which are responsible for destroying unwanted proteins in cells. The new technology, called a molecular radar, reveals which CRLs are deployed to address cellular stresses and perform the actions of some anti-cancer drugs.
Researchers at Mayo Clinic discovered that senescent macrophages in the lung promote tumor growth by blocking the immune system's response to abnormal cell growth. Eliminating these senescent cells delays tumor formation, suggesting a potential therapeutic target for cancer treatment.
Penn State researchers develop a bubble-based technique to visualize macrophages in mammal tissue, offering insights into immune system regulation and potential therapies. The approach enables real-time monitoring of immune cells, which could lead to more effective cell-based treatments for conditions like cancer and autoimmune disorders.
Researchers at Nagoya University developed a unique supramolecule to remove cholesterol from macrophages, stopping the development of non-alcoholic steatohepatitis (NASH) in mice. Cholesterol crystals are also found in human patients, suggesting a potential therapeutic strategy.
Researchers developed a personalized combination treatment that turned on an immunometabolic switch to effectively control aggressive prostate cancer. The treatment showed complete tumor control and long-lasting survival without side effects in a mouse model of advanced prostate cancer.
The study reveals 15 distinct macrophage subtypes, including microglia-like cells and proangiogenic macrophages, which play critical roles in early tissue development. Macrophages were found to influence neural crest cell differentiation and contribute to vascular development during prenatal stages.
Defective exosomes in diabetic patients drive inflammation and impair wound healing. Researchers identified alterations in exosome cargo and release that compromise wound healing in diabetes. New exosome-focused therapies may promote healing of chronic wounds.
Researchers discuss the essential role of macrophages in metastatic growth of lung colonies in melanoma, highlighting their importance in clearing challenges to tissue integrity and promoting growth-related processes. The authors emphasize the need for targeted therapies against macrophages to combat untreatable metastasis.
Researchers have deciphered a biochemical mechanism explaining how cortisone preparations mediate inflammation-resolving effects in human immune cells. Cortisone influences enzymes involved in the formation of inflammation-resolving messenger substances, inducing resolvins early but impairing function later.
The study found that black soldier fly larvae oil exhibits anti-inflammatory properties, suppressing proinflammatory cytokines and improving colon health. BSFL oil's unique compound profile may offer a new approach to managing inflammatory diseases.
A study found that border-associated macrophages play a crucial role in neuroinflammation and neurodegeneration in Parkinson's disease. Deleting MHCII from these cells reduced neuroinflammation, suggesting they are essential for presenting alpha-synuclein antigens to T cells.
Researchers at TUM develop an RNA agent for a lung spray that slows macrophage activity, reducing lung inflammation and fibrosis. The active substance RCS-21 is delivered via an inhaler through a special sugar molecule, showing promise in treating acute inflammatory lung damage.
A team of researchers identified a specific subtype of complement-producing macrophages in atherosclerotic lesions that exacerbate plaque necrosis and cardiovascular events. The study suggests a potential therapeutic target to control complement activation within cells, which may also apply to other chronic inflammatory diseases.
Researchers at Massachusetts General Hospital discovered a critical protein, NLRP11, that alerts the body to bacterial infections and initiates an effective immune response. This finding may lead to improved 'humanized' mouse models of infections and diseases involving the immune system.
Researchers found that expression of CiDRE in alveolar macrophages makes patients more susceptible to SARS-CoV-2 invasion and promotes cytokine storm. The genetic quirk is associated with severe COVID-19 symptoms, suggesting potential treatments targeting IL-10R and CiDRE.
Researchers at UC Riverside discovered that female mice secrete more RELMalpha, an immune protein, which protects them against obesity and inflammation. In contrast, male mice have lower levels of RELMalpha, leading to increased inflammation and obesity.
Researchers at the University of Virginia Health System discovered that improper calcium signaling in mitochondria accelerates chronic inflammation, leading to age-related conditions. Increasing calcium uptake in macrophages may help prevent harmful inflammation and its effects on the brain.
Researchers discovered that nickel-cobalt alloy nanocrystals inhibit the activation of three inflammasomes, including NLRP3, NLRC4, and AIM2, in primary macrophages. The study found that these nanocrystals effectively treated colitis and acute peritonitis by reducing disease symptoms.
A study published in Science reveals that ganglia in the neck region are responsible for disrupting melatonin production and causing sleep disturbances in people with heart conditions. Researchers found that macrophages accumulate in the ganglion, leading to inflammation and scarring, which can be treated with drugs.
Massachusetts General researchers discover that macrophages and their proteins contribute to AFib's irregular heartbeat patterns. Inhibiting macrophage recruitment reduces AFib, suggesting a promising strategy for treatment.
A study by Forsyth Institute researchers reveals a link between periodontal disease and amyloid plaque formation in the brain. Oral bacteria can travel to the brain, causing neuroinflammation and promoting cognitive decline in Alzheimer's patients.
Researchers discovered a protein, C/EBPα, that accelerates B lymphocyte-to-macrophage conversion by interacting with PU.1. This epigenetic mechanism may be targeted for cancer research and treatment.
Researchers at the University of Pennsylvania School of Engineering and Applied Science have developed a new therapy that uses engineered macrophages to eliminate solid tumors. The treatment works by silencing a molecular pathway that prevents white blood cells from attacking cancer cells, allowing them to recognize and destroy tumoroids.
Two studies investigate long-term consequences of COVID-19, identifying potential drug targets for treating chronic disease. Researchers found novel pathways in the lungs and immune system that may lead to effective treatment options, including therapies targeting immune dysfunction and mucous cell differentiation.
Researchers at USP in Brazil discovered that Leishmania parasites manipulate the protein gasdermin-D to prevent the immune system from killing them. This allows the parasite to continue replicating and causing disease. The findings offer hope for developing novel treatments for leishmaniasis, a disease affecting 30,000 people annually.
Scientists have created a new way to image and track macrophages in the body using ultrasound-enhanced immune cells. This method has potential for early cancer detection and monitoring of therapeutic efficacy. The technique involves attaching microbubbles to macrophages, allowing for high-resolution tracking images.
Researchers have developed a new immunotherapy targeting tumour macrophages, which are immunosuppressive cells that weaken the immune system. The treatment, RImAb, reduces tumour growth and modifies the tumour microenvironment, offering potential for a new line of treatment for lung cancer patients.
Researchers have discovered that most immune cells contributing to chronic inflammation in severe COVID-19 are not infected with the SARS-CoV-2 virus. Instead, these uninfected macrophages detect damage and trigger a strong inflammatory response, leading to excessive collateral damage.
Researchers at Moffitt Cancer Center found that tumor-associated macrophage clustering in the stromal compartment is associated with poor outcomes. The study developed a score based on gene expression to predict macrophage clustering, which also predicted disease stage and survival.
A cell therapy using myeloid cells bound to drug delivery microparticles reduces disease burden in a preclinical multiple sclerosis model. The therapy partially reverses hind limb paralysis and improves motor functions.
A study from MedUni Vienna found that macrophages in the duodenum control iron absorption by degrading transferrin. This discovery may lead to new treatment options for inflammatory bowel diseases and intestinal infections.
Researchers have found a new target and drug combination that appears to stop the destruction of vision in premature newborns. By blocking ACAT1, an enzyme that converts cholesterol into smaller pieces, scientists can prevent the formation of leaky blood vessels and inflammation in the retina.
A study by University of Alabama at Birmingham researchers reveals that cadmium-induced inflammation increases the severity and mortality of lung infections. The findings suggest that targeting the regulation of PPAR-gamma in macrophages may protect against severe pneumonia.
Researchers at Nagoya University found an alternative route for microglia colonization in the embryonic brain, suggesting a novel approach to combat diseases like fetal brain dysfunction. Macrophages can convert into microglia later in development, providing new insights into microglial plasticity and behavior.
A recent study published in the journal Immunity has shed light on the immune response to parasitic worm infection, revealing a critical role for T cells and macrophages. The research team identified specific signaling molecules that control the development of tissue-resident macrophages, which are essential for eliminating the infection.
Researchers found that applying ice to minor muscle damage in rats enhances muscle repair and reduces inflammation. The study used an animal model of mild injuries and showed that icing attenuates the recruitment of pro-inflammatory macrophages, preventing injury expansion. This contradicts previous findings on the negative effects of ...
Researchers at Ritsumeikan University have made a breakthrough in understanding how macrophages recognize microplastics, discovering an interaction between aromatic rings that drives this process. The study suggests that while microplastics may not induce acute inflammation, chronic exposure could lead to autoimmune diseases.
Scientists have identified monocytes, a type of white blood cell, as a potential target for eliminating HIV infections. A new study found that monocytes can harbor stable HIV genomes, which may provide a new direction for efforts to improve therapies and eventually cure the disease.
Researchers have developed a novel probe, CDg18, to selectively dye M2 macrophages, which are associated with cancer progression. This breakthrough enables real-time monitoring of macrophage reprogramming in cancerous tissues, holding promise for new cancer treatments.
A new study confirms that HIV can persist in myeloid cells for months to several years, even in virally suppressed individuals. The findings suggest that these cells contribute to a long-lived HIV reservoir and may be an important target for cure efforts.
A new study found a protein that regulates macrophage function, clearing residues from regenerating muscle and recovering regenerative capacity in aged mice. The discovery holds promise for regenerative medicine and aging, potentially improving the success of current stem-cell based therapies.
Researchers at the Francis Crick Institute have discovered a key role for autophagy in controlling intracellular infections like TB. By boosting this natural process, they hope to create new treatments that can combat antibiotic-resistant bacteria.
A study published in Cell Death & Disease reveals that a protein cross-linking enzyme called TG2 exacerbates kidney fibrosis by polarizing M2 macrophages. The researchers hope to develop treatments for diseases caused by inflammation imbalance, such as fibrosis, cancer, and atherosclerosis.
Researchers created a three-dimensional structure that mimics bone and houses osteosarcoma cells beside immune cells, finding increased inflammation reduces chemotherapy effectiveness. The study highlights the importance of the tumor microenvironment in disease progression and treatment.
A comprehensive analysis of invasive ER+ breast cancers found macrophages as dominant immune cells infiltrating tumors. The study identified distinct immune cell 'neighborhoods' associated with good patient outcomes and highlights the need for tailored immunotherapies targeting macrophages.
Researchers discovered that lipid deposition on medical implant surfaces can signal to the immune system whether to attack or ignore the implant. This knowledge could help develop biomaterials that deflect host immune aggression, reducing malfunction rates for devices like pacemakers and surgical mesh.
Researchers at Kyoto University found that neutrophils instruct macrophages to form a bacteria-permissive microenvironment, which could have implications for cancer treatment. The study suggests that A9, an enzyme expressed in neutrophils, may play a key role in this process.
Researchers found that Fumarate Hydratase is repressed in macrophages, leading to the release of cytokines and worsening inflammation. Restoring or targeting this enzyme could lead to new anti-inflammatory therapies for diseases like Lupus and sepsis.
Researchers have developed novel biomimetic polypeptides that activate M1-like macrophages, a type of immune cell involved in fighting cancer. The new immunomodulators, known as BMPPs, exhibit excellent biocompatibility and efficacy, making them a promising tool for cancer therapy.
Reducing mRNA methylation promotes migration of macrophages into the brain and clearance of toxic protein amyloid-beta. This pathway provides a potential new target for treatment of Alzheimer's disease.
Researchers tracked the lifecycle and function of tingible body macrophages, specialized cells that clean up the immune system's waste, in a significant breakthrough. The study sheds light on autoimmune disorders like lupus by understanding the role of these cells in triggering autoimmunity.
Researchers discovered a new personalized immunotherapy combination that treats aggressive forms of advanced prostate cancer. By blocking PD-1-expressing macrophages and Wnt/β-catenin pathway activation, the therapy significantly improves response rates in PTEN-deficient cancers.
Researchers found that immune cells play a key role in hypertension, weakening blood vessel walls and damaging the blood-brain barrier. Inhibiting inflammatory messengers may be a new therapeutic target for treating hypertension.